ASTN2: A Potential Drug Target and Biomarker (G23245)

Target Name: ASTN2

NCBI ID: G23245

ASTN2

ASTN2: A Potential Drug Target and Biomarker

Astrotactin-2 (ASTN2) is a protein that is expressed in various tissues of the human body, including the liver, pancreas, and muscle. It is a member of the actinin family, which is characterized by the presence of a nucleotide-binding oligomerization (NBO) domain in the alpha-helices of actinin proteins.

ASTN2 is unique among its family members because of its ability to form inclusion bodies in the cytoplasm of cells. Inclusion bodies are structures that can be derived from the cytoplasm of a cell, and they are composed of a variety of proteins that are present in the cytoplasm. The NBO domain of ASTN2 is responsible for the formation of these inclusion bodies, and it is believed to play a key role in the regulation of actinin function.

ASTN2 is also of interest as a potential drug target because of its role in the regulation of cell growth and differentiation. In addition, because ASTN2 is expressed in a variety of tissues throughout the body, it is potential to serve as a biomarker for a variety of diseases.

ASTN2 has been shown to play a role in the regulation of a variety of cellular processes, including cell growth, differentiation, and inflammation. For example, studies have shown that ASTN2 can inhibit the growth of cancer cells and promote the growth of normal tissues. In addition, ASTN2 has been shown to play a role in the regulation of cell-cell interactions and in the development of tissues.

ASTN2 is also of interest as a potential drug target because of its role in the regulation of insulin sensitivity. Insulin sensitivity is a condition in which the body's cells become less responsive to insulin, making it difficult for the body to regulate its blood sugar levels. ASTN2 has been shown to play a role in the regulation of insulin sensitivity and may be a potential target for a drug that can improve insulin sensitivity in people with type 2 diabetes.

ASTN2 is also of interest as a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Because ASTN2 is expressed in a variety of tissues throughout the body, it is potential to serve as a useful biomarker for a variety of diseases.

In conclusion, Astrotactin-2 (ASTN2) is a protein that is expressed in various tissues of the human body and is of interest as a potential drug target and biomarker. Its unique ability to form inclusion bodies in the cytoplasm and its role in the regulation of cell growth, differentiation, and insulin sensitivity make it a promising target for drug development. Further research is needed to fully understand the role of ASTN2 in the regulation of cellular processes and its potential as a drug and biomarker.

Protein Name: Astrotactin 2

Functions: Mediates recycling of the neuronal cell adhesion molecule ASTN1 to the anterior pole of the cell membrane in migrating neurons. Promotes ASTN1 internalization and intracellular transport of endocytosed ASTN1 (By similarity). Selectively binds inositol-4,5-bisphosphate, inositol-3,4,5-trisphosphate and inositol-1,3,4,5-tetrakisphosphate, suggesting it is recruited to membranes that contain lipids with a phosphoinositide headgroup (Ref.6)

The "ASTN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASTN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets